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OBJECTIVES: To explore the trends in physicians’ prescribing
of promotional targeted drugs (PTD) in two categories—Statins
and COX-2 inhibitors, before and after implementing the phar-
maceutical policies which included the National Essential Drug
List (NEDL), the health beneﬁt schemes, and the regulation 
of the hospital Pharmacy & Therapeutic Committee (PTC).
METHODS: Electronic outpatient prescription records of the
PTDs and the established drugs in the same category at a teach-
ing hospital were compared. Data on how and when the PTD
got approved by the PTC including the prescribing restrictions
were also assembled. A time series analysis of prescription data
for each drug was constructed and marked for any known phe-
nomena during 1998–2004. RESULTS: The highly promoted
drugs in both groups showed signiﬁcant increases in drug uses
after the implementation of pharmaceutical policies especially 
if the drug was listed in the NEDL. The majority of the drug
costs were acquired by cash payment and the price for expensive
drugs varied between 5–10 times that of the alternatives in the
same category. While the sales shares for expensive drugs
increased enormously, the trend decreased drastically for the
alternative drugs. Among the health schemes, the Civil Servants
Medical Beneﬁt Scheme beneﬁciaries were likely get expensive
drugs than others. CONCLUSIONS: This exploratory study
reveals the different types of pharmaceutical policies that can
have an impact on the trend of physicians’ PTD prescribing. The
ﬁndings call for further in-depth investigation of critical factors
inﬂuencing physician prescribing behavior of PTDs in order to
curb the escalating drug cost and promote rational drug use in
the country.
PHP44
COST AVOIDANCE OF CLINICAL PHARMACIST
INTERVENTIONS AT A UNIVERSITY TEACHING HOSPITAL
Howe AM
Grady Health System, Altanta, GA, USA
OBJECTIVE: The purpose of this evaluation was to identify the
types of interventions made by clinical pharmacists, determine
the cost avoidance of pharmacist interventions and incorporate
the information into a new system at Grady Health System.
METHODS: Two phases were required to characterize the type,
cost avoidance and total number of daily documented interven-
tions made by clinical pharmacists from April 1998 to July 2003.
A third phase was used to evaluate interventions made from June
2004–May 2005. Interventions were classiﬁed by the interven-
tion type, assigned cost avoidance and the assigned a probabil-
ity of likely occurrence of an event without intervention. Data
was collected in phase two of the evaluation to determine the
average documented daily interventions per clinical pharmacist
and the total cost avoidance of clinical pharmacist interventions
for the department. RESULTS: A total of 1,871 (29.6%) of
6,311 documented interventions were reviewed. There was an
average of 4.9 interventions per adjusted workday documented.
The average cost avoidance of a documented intervention 
was $288. The daily adjusted work day cost avoidance was
$1411.20 or an annual cost avoidance of $338,688 for the 64
month time period. If extrapolated to the entire data set, the cost
avoidance would be $1,798,567. In the second phase of the
project, the average number of daily interventions documented
by a clinical pharmacist was 5.5 (SD ± 1.2) resulting in an extrap-
olated annual cost avoidance of $380,160 per clinical pharma-
cist. In the ﬁnal phase of the project, the average number of
interventions increased to 26.2/day or a total of 9,552 pharma-
cist interventions. The cost to the health system is $128,941 
in pharmacist salary dollars with cost avoidance savings of
$2,037,863. CONCLUSION: The return on investment of the
system was $16 for every dollar spent on clinical pharmacy ser-
vices. Each intervention saves $213 for the health system.
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APPRAISAL OF FIVE NEW OUT-OF-HOURS (OOH) 
PRIMARY CARE CENTRES IN THE PARISIAN REGION:
“MAISONS MÉDICALES DE GARDE (MMG)”
Lemasson H1, Jasso Mosqueda J2, Chicoye A2
1AREMIS Consultants, Neuilly Sur Seine, Ile de France, France;
2AREMIS Consultants, Neuilly Sur Seine, France
French GPs are increasing reluctant to dispense medical services
in OOH because of security concerns and lack of economic
incentives. In order to motivate GPs to participate to OOH care,
experimental MMGs have been set up. A medical ofﬁce is shared
by GPs on duty to provide medical services in predetermined
time schedules. Referrals to MMG are determined by emergency
dispatching centres (C15) and/or hospital emergency depart-
ments (HED). GPs receive a forfeit, adjusted with effectively dis-
pensed visits. Facilities are secured. OBJECTIVE: To assess the
5 MMG activity in comparison to HED, C15 and other home
cares and patients and professionals satisfaction. METHODS:
“Before-after” assessment month 2 to 6 after MMGs were set
up and reproduced at month 14 to 18. Quantitative data were
collected from MMGs, “C15”, HED and health insurance.
Questionnaires were submitted to patients (visiting/calling HED,
“C15”, GPs practices or MMG, n = 537), and professionals (GPs
involved in MMGs, HED and C15 professionals n = 389).
RESULTS: Half of the practitioners in MMGs area participated.
Most patients (95%) were in need of primary care. On weekend
days, number of visits to MMG were approximately equivalent
or superior to an ofﬁce based GP (22), but on weekdays
(8pm–12pm) average number of visits was low (<4). Patients and
GPs were satisﬁed with services. MMGs however can not meet
all OOH needs, particularly home visits. Although they differ in
organisation, there is room for optimization for all MMGs. Pro-
fessionals are unable to deﬁne precisely OOH primary care, and
communication to patients, highly desirable, is not yet harmo-
nized. CONCLUSION: MMG should be encouraged but provide
only partial response, as a global approach including home visits
is needed.
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1Sanoﬁ-Aventis, Bridgewater, NJ, USA; 2Good Samaritan Hospital,
Dayton, OH, USA; 3PharMetrics, Inc, Watertown, MA, USA;
4Walgreens Health Services, Deerﬁeld, IL, USA; 5West Virginia
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OBJECTIVE: To propose a deﬁnition of compliance/adherence
and persistence which would be widely agreed and useful in pro-
viding consistency for clinical, health policy and clinical practice
research. METHODS: The “Issues and Deﬁnitions Working
Group” of the Medication Compliance Special Interest Group
undertook to review deﬁnitions that could be used for medica-
tion compliance/adherence and persistence. Broad deﬁnitions
were presented at an ISPOR workshop in 2003 and revised
accordingly. These deﬁnitions were then placed on the ISPOR
website and all members were given an opportunity to comment
and vote on deﬁnitions in December 2004. Although consensus
was reached for the compliance and persistence deﬁnitions, many
key issues related to these deﬁnitions required resolution. At the
Annual Meeting 2005, a workshop was held to discuss the issues
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around operationalizing compliance/adherence and persistence
deﬁnitions. Comments were incorporated and the ﬁnal opera-
tional deﬁnitions posted for consensus on the website. RESULTS:
Medication Compliance (Synonym: Adherence) is the extent to
which a patient acts in accordance with the prescribed interval
and dose as well as dosing regimen. The unit of measure for com-
pliance is administered doses per deﬁned period of time, reported
as a proportion (%) of prescribed doses (D) taken at the pre-
scribed time interval (T) as measured by the period of time, i.e.,
% of TD, measured by percentage. CONCLUSION: Medication
Persistence is the duration of time patient remains on treatment
i.e. accumulation of time from initiation to discontinuation of
therapy, where patient is deﬁned as a discontinuer if medications
were not taken within a predeﬁned permissible time gap.
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EVALUATION OF THE RELATIONSHIP BETWEEN
PHARMACEUTICAL PRODUCT PRICE AND HEALTH-RELATED
QUALITY OF LIFE USING WHOLESALE ACQUSITION COST
AND AVERAGE EFFECT SIZE
Murawski MM1, Mychaskiw MA2
1Purdue University, West Lafayette, IN, USA; 2Pﬁzer, Inc, New York,
NY, USA
OBJECTIVES: The objective of this study was to evaluate the
relationship between pharmaceutical product price and its ability
to improve patient health related quality of life (HRQoL).
METHODS: Comprehensive review of the literature was con-
ducted to identify all HRQoL studies of pharmaceutical prod-
ucts that utilized a test-retest experimental approach. Effect sizes
were calculated from data available for 31 products, represent-
ing a brand range of therapeutic areas. Wholesale acquisition
cost (WAC), number of months on market, and number of prod-
ucts in therapeutic class was collected for each product. Cost per
day of therapy was calculated using recommended starting dose
in the labeling. Multivariate linear regression models were con-
structed where either WAC or cost per day of therapy at rec-
ommended starting dose was the dependent variable and effect
size, number of months on market, and number of products in
therapeutic class were independent variables. Diagnostics were
performed to verify model assumptions. RESULTS: Using mul-
tivariate linear regression, average effect size, number of prod-
ucts in therapeutic class, and number of months on market were
signiﬁcant predictors of WAC [b (average effect size) = 167.13,
p < 0.0001; b (number in class) = 14.85, p < 0.0001; b (number
of months on market) = -0.47, p = 0.0001; R-square = 0.65].
Diagnostics revealed no violations of model assumptions. CON-
CLUSIONS: There is sufﬁcient evidence to suggest that there is
a direct relationship between a pharmaceutical product’s ability
to cause improvement in HRQoL and the price of the product,
measured using average effect size and WAC, respectively. In
addition, the number of products within a therapeutic class and
their length of time on the market were inﬂuential of drug price.
Further research should be conducted to evaluate the impact of
prescription medications on HRQoL, and, to identify and char-
acterize the effects of drug and marketplace variables on drug
prices.
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A SURVEY OF PATIENT REPORTED OUTCOME (PRO) CLAIMS
IN PHARMACEUTICAL ADVERTISING
Yuwaree V, Rojsutee S,Thavorncharoensap M
Mahidol University, Rajathevi, Bangkok,Thailand
OBJECTIVE: To investigate the quantity and quality of Patient
Reported Outcome (PRO) claims in pharmaceutical advertise-
ments in 2 Thai medical journals. METHOD: A retrospective
review of all pharmaceutical advertisements in the 2004 issues
of 2 Thai medical journals (Clinic and Pharmatime) was per-
formed by 3 trained pharmacists. Two reviewers independently
reviewed the advertisements. If the reviewers disagreed the ﬁnal
decision was made by the third reviewer. All distinctive phar-
maceutical advertisements were classiﬁed into claim advertise-
ment or reminder advertisement. PRO claims and economic
claims were also identiﬁed. Then, the advertisements were cate-
gorized according to their reference statuses. Finally, the review-
ers evaluated whether the cited references provided substantial
evidence to support the claims. RESULTS: From 183 advertise-
ments reviewed, there were 48 distinctive advertisements. Forty-
ﬁve (0.94%) and three (0.06%) of the advertisements were
classiﬁed as claim advertisement and reminder advertisement,
respectively. Nineteen (0.42%) of the claim advertisements con-
tained PRO claims while two (0.04%) of the claim advertise-
ments contained economic claims. The result indicated that only
16 (0.36%) of the claim advertisements cited at least one pub-
lished article retrievable from Medline as references, while the
remaining 29 (0.64%) contained no reference or cited package
inserted or non-published data on ﬁle as references. When
looking closely at PRO claims, it was found that 12 (0.63%) of
the PRO claims were misleading because the outcomes stated in
the claims was not supported by the given references. In addi-
tion, there was not sufﬁcient evidence to support all 2 economic
claims. CONCLUSION: More than half of the PRO claims were
misleading. Practitioners should be cautious in assessment of
PRO claim advertisements in medical journal. There is also a
substantial need for more rigorous regulation of PRO claims.
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COST EFFECTIVENESS OF ESCITALOPRAM IN THE
TREATMENT OF GENERALIZED ANXIETY DISORDER (GAD)
Walker JH1, Bereza BG1, Hemels M2, Le Melledo JM3, Iskedjian M1,
Einarson T4
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2H. Lundbeck A/S, Paris, France; 3University of Alberta, Edmonton, AB,
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OBJECTIVE: To determine the cost-effectiveness of escitalopram
in the treatment of Generalized Anxiety Disorder (GAD) in
Canada. GAD places a signiﬁcant burden on primary care
resources, exhibiting an 8% prevalence rate among patients seen
by primary care clinicians. METHODS: A 24-week decision tree
analytic model was constructed using Tree Age Data® Pro Suite.
Patients received treatment for GAD with either escitalopram or
generic paroxetine. Clinical rates were determined from a review
of the literature; expert opinion guided model development in
establishing decision pathways. Tolerance/intolerance to the
initial drug was incorporated into the model, which included
augmenting, titrating or switching comparators. Psychotherapy
was used for patients not responding to either drug, or to the
combination of either drug augmented with a benzodiazepine.
Costs were measured in undiscounted 2005 Canadian dollars
(CAD). Resources were valued using standard Canadian sources.
Effectiveness was measured in Symptom Free Days (SFDs).
Analyses were performed from two perspectives: the Ontario
Ministry of Health and Long Term Care (MoH—included all
direct costs: drugs, physicians visits), and societal (SOC-included
direct plus indirect costs weighted using the average industrial
wage). Extensive sensitivity analyses (1-way and probabilistic)
were conducted. RESULTS: Results shown are preliminary. Base
case analyses (MoH perspective) yielded an incremental cost of
$24 for escitalopram (expected cost = $713 for 85 SFDs) over
